Clozapine for the treatment of agitated-depressed patients with cognitive impairment: a report of three cases.
Clozapine, an atypical antipsychotic, is mainly approved for the treatment of resistant schizophrenia. However, a substantial body of evidence suggests that it might be useful in other psychiatric indications, such as treatment-resistant depression, Parkinson's disease, and dementia. In this report we present the cases of three patients hospitalized at the psychiatric division of the Sheba Medical Center, diagnosed with major depressive disorder with cognitive impairment, whose presenting symptom was agitation. These patients were nonresponders to various treatment modalities. However, treatment with clozapine brought about a favorable response.
Nacasch
N
N
Department of Psychiatry C, Sheba Medical Center, Ramat-Gan, Israel.
Dolberg
O T
OT
Hirschmann
S
S
Dannon
P
P
Grunhaus
L J
LJ
D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003024:Clozapine / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D003863:Depression / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011595:Psychomotor Agitation / Q000188:drug therapy
D014150:Antipsychotic Agents; D003024:Clozapine